logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
X

Xiaohua Zeng

Chongqing Cancer Hospital
H指数:9
被引数:462

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pathological response and metabolites’ prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial

病理反应和代谢物的预后作用：在HER2阳性乳腺癌患者中接受新辅助吡咯替尼、曲妥珠单抗、白蛋白结合型紫杉醇和卡铂治疗的单臂II期试验

Breast Cancer Research
IF5.6
2025-10-300
OAAI
Mei Liu; La Zou; Ningning Zhang; Wenqi Zhou; Xianjun Pan; Yongchun Deng; Yeli Yue; Jing Wu; Xinrui Liang; Maoshan Chen; Xiaohua Zeng
Lerociclib plus fulvestrant in patients with HR+/HER2-locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial

Lerociclib联合fulvestrant用于接受过先前内分泌治疗并进展的HR+/HER2-局部晚期或转移性乳腺癌患者的治疗：LEONARDA-1一项III期随机试验

NATURE COMMUNICATIONS
IF15.7
2025-01-160
OA
Xu, Binghe; Zhang, Qingyuan; Luo, Yang; Tong, Zhongsheng; Sun, Tao; Shan, Changping; Liu, Xinlan; Yao, Yumin; Zhao, Bing; Wang, Shusen; Zeng, Xiaohua; Hu, Changlu; Yan, Xi; Wang, Xiaojia; Jia, Hongyan; Chen, Zhendong; Qiu, Fuming; Wu, Xinhong; Zhang, Deyong; Li, Tong
A Single-Arm Phase II Clinical Trial of Fulvestrant Combined with Neoadjuvant Chemotherapy of ER+/HER2-Locally Advanced Breast Cancer: Integrated Analysis of 18F-FES PET-CT and Metabolites with Treatment Response

一项Fulvestrant联合新辅助化疗治疗ER+/HER2-局部晚期乳腺癌的单臂II期临床试验：治疗反应与18F-FES PET-CT及代谢物的综合分析

CANCER RESEARCH AND TREATMENT
IF3.8
2025-01-150
OA
Shao, Qing; Zhang, Ningning; Pan, Xianjun; Zhou, Wenqi; Wang, Yali; Chen, Xiaoliang; Wu, Jing; Zeng, Xiaohua
Efficacy, Safety, and Immunogenicity of TQ-B211 (a Trastuzumab Biosimilar) Plus Docetaxel versus Herceptin® Plus Docetaxel for HER2-positive Metastatic Breast Cancer: a Double-blind, Randomised, Multicenter, Phase 3 Trial
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Hu, Xichun; Zhang, Qingyuan; Wang, Shusen; Sun, Tao; Zeng, Xiaohua; Xie, Weimin; Tong, Zhongsheng; Cao, Hui; Xiong, Huihua; Wang, Xiuwen; Yang, Jin; Zhang, Shuqun; Wang, Ying; Hu, Chunhong; Lei, Kaijian; Ma, Binlin; Liu, Wei; Yu, Zhiyong; Peng, PeiJian; Yang, Hongwei; Yuan, Zhijun; Wang, Xiaojia; Wang, Xujuan; Wang, Hong; Shu, Yongqian; Li, Nanlin; Yue, Wenbin; Wang, Jingfen; Wang, Daqing; Luo, Zhiguo; Mo, Junyang; Li, Yarong; Sheng, Lili
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Pyrotinib与安慰剂联合曲妥珠单抗和多西他赛作为HER2阳性转移性乳腺癌患者的一线治疗 (PHILA): 随机，双盲，多中心，3期试验

BMJ-BRITISH MEDICAL JOURNAL
IF42.7
2023-10-3134
OAAI
Ma, Fei; Yan, Min; Li, Wei; Ouyang, Quchang; Tong, Zhongsheng; Teng, Yuee; Wang, Yongsheng; Wang, Shusen; Geng, Cuizhi; Luo, Ting; Zhong, Jincai; Zhang, Qingyuan; Liu, Qiang; Zeng, Xiaohua; Sun, Tao; Mo, Qinguo; Liu, Hu; Cheng, Ying; Cheng, Jing; Wang, Xiaojia; Nie, Jianyun; Yang, Jin; Wu, Xinhong; Wang, Xinshuai; Li, Huiping; Ye, Changsheng; Dong, Fangli; Wu, Shuchao; Zhu, Xiaoyu; Xu, Binghe
Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double- blind, placebo-controlled, phase 3 trial
ACTA PHARMACEUTICA SINICA B
IF14.6
2023-05-0116
OAAI
Xu, Binghe; Zhang, Qingyuan; Hu, Xichun; Li, Qing; Sun, Tao; Li, Wei; Ouyang, Quchang; Wang, Jingfen; Tong, Zhongsheng; Yan, Min; Li, Huiping; Zeng, Xiaohua; Shan, Changping; Wang, Xian; Yan, Xi; Zhang, Jian; Zhang, Yue; Wang, Jiani; Zhang, Liang; Lin, Ying; Feng, Jifeng; Chen, Qianjun; Huang, Jian; Zhang, Lu; Yang, Lisong; Tian, Ying; Shang, Hongyan
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-10-241
OAAI
Yan, Min; Yuan, Peng; Ouyang, Quchang; Cheng, Ying; Han, Guohui; Wang, Dewei; Ran, Li; Sun, Tao; Zhao, Da; Bai, Yuju; Yang, Shun'e; Wang, Xiaojia; Wu, Rong; Zeng, Xiaohua; Yao, Herui; Ji, Xuening; Jiang, Jun; Hu, Xiaohua; Lin, Haifeng; Zheng, Liping; Zhu, Zhitu; Ge, Wei; Yang, Junlan; Cui, Tongjian; Zhang, Xiaozhi; Lu, Fangyang; Li, Wenhui; Xu, Hongyan; Kang, Mafei; Gong, Ping; Zou, Liqun; Liu, Jiang; Zhang, Hongliang; Yu, Hao; Xu, Binghe

研究方向

暂未获取到该数据
Q
Qing Shao
H 指数:24论文数:163被引数:2,428
徐兵河 封面图
徐兵河
H 指数:63论文数:785被引数:2.8万
S
Shusen Wang
H 指数:39论文数:237被引数:6,448
Q
Quchang Ouyang
H 指数:23论文数:139被引数:2,536
李威 封面图
李威
H 指数:107论文数:2,240被引数:7.2万
孙
孙涛
H 指数:48论文数:246被引数:6,853
孙涛 封面图
孙涛
H 指数:28论文数:181被引数:3,804
W
Wenqi Zhou
H 指数:6论文数:29被引数:119
J
Jiuquan Zhang
H 指数:36论文数:250被引数:3,952
孙涛 封面图
孙涛
H 指数:43论文数:353被引数:1.1万